Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]

Hasler-Strub, U.; Mueller, A.; Li, Q.; Thuerlimann, B.; Ribi, Karin; Gerber, S.; Moos, R. von; Fehr, M.; Rochlitz, C.; Zaman, Khalil; Aebi, Stefan; Hochstrasser, A.; Gick, U.; Baertschi, D.; Greuter, S.; Schreiber, A.; Caspar, C.; Trojan, A.; Condorelli, R.; Ruhstaller, Thomas

doi:10.1016/j.jgo.2022.09.001

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At baseline, the median age was 76 years (range, 70−89), 64% of patients had coexisting morbidities and 45% had liver metastases. 32 The primary endpoint was not reached, with a DCR of 40% at a median follow-up of 25.6 months. The ORR was 22%, including a CR rate of 2.6% and a PR rate of 19.5%.…”

Section: Sakk 25/14: Eribulin As First-line Treatment In Older Patien...mentioning

confidence: 98%

“…The multicenter phase II SAKK 25/14 trial investigated the efficacy of a reduced starting dose of eribulin (1.1 mg/m 2 on Day 1 and Day 8) as frontline treatment in 77 older patients (≥70 years) with metastatic breast cancer. 32 The primary endpoint was a disease control rate (DCR) of ≥55%.…”

Section: Sakk 25/14: Eribulin As First-line Treatment In Older Patien...mentioning

confidence: 99%

See 1 more Smart Citation

Recent Developments in Treatment of Older Patients with Breast Cancer

2024

healthbook TIMES Onco Hema

View full text Add to dashboard Cite

Breast cancer is the most frequently diagnosed malignancy in women. Aging is an independent predictor of adverse treatment outcomes, including an increase in multimorbidity, which is associated with higher mortality, functional impairment, poor quality of life (QoL) and elevated healthcare utilization and costs. Geriatric screening tools and assessments that evaluate a patient's fitness and frailty status are becoming increasingly important in providing a comprehensive patient profile and developing an optimized treatment plan. However, older patients are currently underrepresented in clinical trials, resulting in a lack of published data. This article examines the results from recent clinical trials in breast cancer, with a focus on older patient populations.

show abstract

Section: Sakk 25/14: Eribulin As First-line Treatment In Older Patien...mentioning

confidence: 98%

Section: Sakk 25/14: Eribulin As First-line Treatment In Older Patien...mentioning

confidence: 99%

Recent Developments in Treatment of Older Patients with Breast Cancer

2024

healthbook TIMES Onco Hema

View full text Add to dashboard Cite

show abstract

The therapeutic potential and application of marine alkaloids in treating breast cancer

Yu,

Wang,

et al. 2024

Front. Mar. Sci.

View full text Add to dashboard Cite

Breast cancer is a major threat to women’s health worldwide. Although the 5-year survival rate is relatively high, treating recurrent and metastatic breast cancer remains challenging. Existing anticancer drugs are often accompanied by adverse reactions; thus, there is an urgent need to explore safer and more effective treatment options. Marine natural compounds, especially alkaloids, are considered to be a potential treasure trove of new anticancer drugs due to their unique chemical structure and wide range of biological activities. A variety of marine alkaloids against breast cancer, including ecteinascidins, halichondrins, manzamines, and trabectedins, have opened new avenues for breast cancer treatment by employing multiple mechanisms, such as inducing cell apoptosis and autophagy, blocking cell cycle, inhibiting angiogenesis, targeting oncogene pathways, and inhibiting metastasis and invasion. Currently, Yondelis (trabectedin) has completed phase II clinical trials in patients with breast cancer and has shown certain efficacy. However, the clinical application of marine alkaloids still needs further research and development. This article deeply explores the mechanism of action of marine alkaloids against breast cancer and anticipates their clinical application prospects. With the deepening of research and the advancement of development, marine alkaloids are expected to bring new breakthroughs in breast cancer treatment.

show abstract

Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]

Cited by 2 publications

References 16 publications

Recent Developments in Treatment of Older Patients with Breast Cancer

Recent Developments in Treatment of Older Patients with Breast Cancer

The therapeutic potential and application of marine alkaloids in treating breast cancer

Contact Info

Product

Resources

About